NWL 154 - New World Laboratories
Alternative Names: NWL-154 - New World LaboratoriesLatest Information Update: 06 Nov 2023
At a glance
- Originator New World Laboratories
- Class Antidementias; Peptidomimetics
- Mechanism of Action Caspase 6 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Huntington's disease
Most Recent Events
- 26 Sep 2023 Preclinical trials in Alzheimer's disease in Canada (unspecified route), prior to September 2023 (New World Laboratories pipeline, September 2023)
- 26 Sep 2023 Preclinical trials in Huntington's disease in Canada (unspecified route), prior to September 2023 (New World Laboratories pipeline, September 2023)